NAMS

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.63
Percentage change 2.92	%

Peers: JNJ PFE MRK BMY LLY GILD AMGN REGN VRTX BIIB

| Held by: IBB DWAS VHT SBIO GURU ONEQ GWX FHLC FMED SMMV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.88	Insider Own	44.60%	Shs Outstand	112.17M	Perf Week	13.93%
Market Cap	2.49B	Forward P/E	-	EPS next Y	-2.03	Insider Trans	-0.46%	Shs Float	62.20M	Perf Month	8.15%
Enterprise Value	1.68B	PEG	-	EPS next Q	-0.49	Inst Own	57.46%	Short Float	11.05%	Perf Quarter	48.79%
Income	-187.36M	P/S	52.80	EPS this Y	30.96%	Inst Trans	27.17%	Short Ratio	8.61	Perf Half Y	-13.23%
Sales	47.14M	P/B	3.20	EPS next Y	-14.66%	ROA	-28.67%	Short Interest	6.88M	Perf YTD	-13.74%
Book/sh	6.93	P/C	3.08	EPS next 5Y	13.98%	ROE	-31.51%	52W High	27.29 -18.76%	Perf Year	6.23%
Cash/sh	7.20	P/FCF	-	EPS past 3/5Y	-22.27% -	ROIC	-24.10%	52W Low	14.06 57.68%	Perf 3Y	124.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.68%	Volatility	5.94% 5.96%	Perf 5Y	-
Dividend TTM	-	EV/Sales	35.66	EPS Y/Y TTM	-816.05%	Oper. Margin	-400.37%	ATR (14)	1.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.98	Sales Y/Y TTM	-	Profit Margin	-397.45%	RSI (14)	67.13	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.98	EPS Q/Q	67.92%	SMA20	14.11%	Beta	-0.03	Target Price	43.27
Payout	-	Debt/Eq	0.00	Sales Q/Q	112.56%	SMA50	15.26%	Rel Volume	1.28	Prev Close	21.54
Employees	68	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	8.48%	Avg Volume	798.93K	Price	22.17
IPO	Feb 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.82% 91.22%	Trades		Volume	1,019,870	Change	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Citigroup	Buy	$42
Jun-10-25	Initiated	Stifel	Buy	$44
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight	$42
Dec-30-24	Initiated	H.C. Wainwright	Buy	$48
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$35
Jan-18-24	Initiated	Guggenheim	Buy	$30
Jan-16-24	Initiated	Piper Sandler	Overweight	$37
Oct-30-23	Initiated	RBC Capital Mkts	Outperform	$25

Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com) -6.38%
Jun-11-25 08:06PM	NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel (Insider Monkey) -6.14%
Jun-09-25 07:00AM	NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial (GlobeNewswire)
Jun-05-25 08:00AM	NewAmsterdam Pharma to Host R&D Day on June 11, 2025 (GlobeNewswire)
May-27-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
08:00AM	Loading…
May-14-25 08:00AM	NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference (GlobeNewswire)
May-12-25 09:55AM	Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know (Zacks)
May-08-25 09:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:15AM	Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates (Zacks)
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-07-25 07:15AM	NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 (GlobeNewswire)
May-02-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-25 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress (GlobeNewswire)
Apr-29-25 11:40AM	NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 01:01PM	Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
04:01PM	Loading…
Apr-17-25 04:01PM	NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors (GlobeNewswire)
Apr-11-25 04:23PM	NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey) +8.60%
Apr-04-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.17%
Mar-31-25 04:18PM	Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? (Investor's Business Daily) -5.93% -10.21%
08:00AM	NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
Feb-26-25 08:00AM	NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.23%
Feb-25-25 08:00AM	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-07-25 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-25 08:00AM	NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-10-25 08:00AM	NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities (GlobeNewswire)
Jan-09-25 03:38PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-24 05:16PM	NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-11-24 09:37PM	NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
05:10PM	Loading…
Dec-10-24 05:10PM	NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug (Investor's Business Daily) +41.41%
04:34PM	NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Dec-06-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-24 07:37AM	NewAmsterdam Pharma Reports Promising Phase 3 Trial Results (TipRanks)
Nov-20-24 04:13PM	NewAmsterdam Dives And Sacrifices A Cup Base Despite A Winning Cholesterol Study (Investor's Business Daily) -15.50%
07:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH (GlobeNewswire)
Nov-18-24 03:20PM	NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-06-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire) +13.73%
Nov-01-24 05:26PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-24 04:30PM	NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November (GlobeNewswire)
Oct-04-24 04:30PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-24 04:32PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-07-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results (GlobeNewswire)
Aug-02-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.35%
Jul-29-24 08:54AM	NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations (Investor's Business Daily) -8.54%
08:00AM	NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Jul-26-24 04:01PM	NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-08-24 08:00AM	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors (GlobeNewswire)
Jul-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-24 08:00AM	NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office (GlobeNewswire)
Jun-07-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 08:00AM	NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings (GlobeNewswire)
May-09-24 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-03-24 04:01PM	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 (GlobeNewswire)
Apr-09-24 08:00AM	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Apr-01-24 08:00AM	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer (GlobeNewswire) -9.64%
Mar-25-24 08:00AM	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress (GlobeNewswire)
Mar-13-24 01:32PM	NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up (Zacks)
Mar-12-24 08:00AM	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD (GlobeNewswire) +11.89%
Feb-28-24 08:33AM	NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-26-24 08:00AM	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-13-24 10:40PM	NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
04:01PM	NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-01-24 04:01PM	NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) -6.01%
Jan-08-24 08:00AM	NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors (GlobeNewswire)
Jan-04-24 08:00AM	NewAmsterdam Pharma Announces 2024 Strategic Priorities (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) -6.91%
08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights (GlobeNewswire)
Oct-31-23 12:05PM	RBC initiates coverage of NewAmsterdam on CETP inhibitor (Yahoo Finance Video) +25.52%
Oct-30-23 09:43AM	AbbVie upgraded, Cisco downgraded: Wall Street's top analyst calls (The Fly) +7.01%
Oct-23-23 08:00AM	NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer (GlobeNewswire) -10.07%
Oct-17-23 03:00AM	Tessellate BIO Emerges from Stealth (GlobeNewswire)
Sep-21-23 07:00AM	NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimers Disease Who Carry an ApoE4 Mutation (GlobeNewswire)
Sep-20-23 08:00AM	NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:01PM	NewAmsterdam Pharma Announces Appointment of William BJ Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer (GlobeNewswire)
Aug-10-23 06:01AM	NewAmsterdam Pharma First Half 2023 Earnings: 0.92 loss per share (vs 1.50 profit in 1H 2022) (Simply Wall St.)
Aug-07-23 07:15AM	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights (GlobeNewswire)
Jul-25-23 04:01PM	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Jun-09-23 04:01PM	NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares (GlobeNewswire)
Jun-06-23 11:25PM	NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares (GlobeNewswire) -16.52%
04:01PM	NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares (GlobeNewswire)
Jun-05-23 07:00AM	NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients (GlobeNewswire)
Jun-03-23 12:15PM	NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 (GlobeNewswire)
May-31-23 08:00AM	NewAmsterdam Pharma to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 08:00AM	NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 (GlobeNewswire)
May-08-23 08:00AM	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights (GlobeNewswire)

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NAP PoolCo B.V.	Affiliate	Jul 14 '25	Proposed Sale	21.56	1,433,193	30,899,641		Jul 14 04:12 PM
Topper James N	Director	Jun 24 '25	Buy	18.43	2,520	46,454	3,024,873	Jun 26 07:41 PM
Topper James N	Director	Jun 25 '25	Buy	18.26	1,260	23,012	3,026,133	Jun 26 07:41 PM
Kling Douglas F	Chief Operating Officer	Jun 16 '25	Option Exercise	10.20	100,000	1,019,709	144,000	Jun 18 04:50 PM
Kling Douglas F	Chief Operating Officer	Jun 16 '25	Sale	19.29	100,000	1,929,141	44,000	Jun 18 04:50 PM
Topper James N	Director	Jun 16 '25	Buy	19.50	8,584	167,381	3,022,153	Jun 18 04:42 PM
NAP PoolCo B.V.	Affiliate	Jun 16 '25	Proposed Sale	19.50	303,197	5,912,342		Jun 18 12:31 PM
LANGE LOUIS G	Director	Jun 01 '25	Option Exercise	0.00	68	0	28,186	Jun 03 04:59 PM
Kling Douglas F	Chief Operating Officer	May 15 '25	Option Exercise	10.00	100,000	1,000,000	144,000	May 19 04:44 PM
Douglas F Kling	Affiliate	May 15 '25	Proposed Sale	18.75	298,612	5,598,975		May 15 04:40 PM
LANGE LOUIS G	Director	May 01 '25	Option Exercise	0.00	69	0	28,118	May 02 04:55 PM
LANGE LOUIS G	Director	Apr 14 '25	Option Exercise	0.00	69	0	28,049	Apr 21 05:41 PM
Kling Douglas F	Chief Operating Officer	Apr 15 '25	Option Exercise	10.00	100,000	1,000,000	144,000	Apr 17 05:41 PM
NAP PoolCo B.V.	Affiliate	Apr 11 '25	Proposed Sale	15.12	1,433,193	21,669,878		Apr 11 05:04 PM
Topper James N	Director	Mar 26 '25	Buy	22.49	1,135	25,521	3,013,569	Mar 28 05:36 PM
Kooij Louise Frederika	Chief Accounting Officer	Mar 26 '25	Option Exercise	0.00	8,269	0	23,269	Mar 28 05:29 PM
LANGE LOUIS G	Director	Mar 26 '25	Option Exercise	0.00	3,102	0	10,062	Mar 28 05:24 PM
Kastelein Johannes Jacob Piete	Chief Scientific Officer	Mar 26 '25	Option Exercise	0.00	45,481	0	79,481	Mar 28 05:20 PM
Kling Douglas F	Chief Operating Officer	Mar 26 '25	Option Exercise	0.00	16,539	0	60,539	Mar 28 05:18 PM
Davidson Michael H.	Chief Executive Officer	Mar 26 '25	Option Exercise	0.00	38,394	0	402,699	Mar 28 05:15 PM
Michael H. Davidson	Affiliate	Mar 26 '25	Proposed Sale	23.41	12,258	286,960		Mar 26 06:19 PM
Douglas F Kling	Affiliate	Mar 26 '25	Proposed Sale	23.41	16,539	387,178		Mar 26 06:00 PM
Kling Douglas F	Chief Operating Officer	Mar 17 '25	Option Exercise	10.00	11,888	118,880	144,000	Mar 19 05:29 PM
Topper James N	Director	Mar 04 '25	Buy	21.02	4,005	84,203	3,012,434	Mar 06 05:32 PM
Kooij Louise Frederika	Chief Accounting Officer	Mar 04 '25	Sale	20.37	150,000	3,055,500	15,000	Mar 05 06:10 PM
Kooij Louise Frederika	Officer	Mar 04 '25	Proposed Sale	20.27	150,000	3,040,500		Mar 04 06:54 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 27 '25	Option Exercise	9.26	46,983	435,063	84,983	Jan 29 05:25 PM
Somaiya Mayur Ian	Chief Financial Officer	Jan 28 '25	Option Exercise	9.26	14,900	137,974	52,900	Jan 29 05:25 PM
Douglas F Kling	Affiliate	Jan 27 '25	Proposed Sale	23.20	500,000	11,600,000		Jan 27 05:09 PM
Mayur Somalya	Affiliate	Jan 27 '25	Proposed Sale	23.20	200,000	4,640,000		Jan 27 04:52 PM
NAP PoolCo B.V.	Affiliate	Jan 10 '25	Proposed Sale	25.31	1,396,241	35,338,860		Jan 10 04:26 PM
ForGrowth NAP B.V.	10% Owner	Dec 30 '24	Sale	25.54	29,846	762,174	10,656,172	Jan 02 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 27 '24	Sale	25.95	41,472	1,076,290	10,686,018	Dec 30 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 26 '24	Sale	26.01	33,438	869,629	10,727,490	Dec 30 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 20 '24	Sale	25.60	49,772	1,274,064	10,802,224	Dec 26 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 23 '24	Sale	25.49	25,132	640,625	10,777,092	Dec 26 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 24 '24	Sale	25.66	16,164	414,831	10,760,928	Dec 26 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 18 '24	Sale	26.10	100,728	2,628,907	10,908,502	Dec 20 04:25 PM
ForGrowth NAP B.V.	10% Owner	Dec 19 '24	Sale	25.45	56,506	1,437,806	10,851,996	Dec 20 04:25 PM
ForGrowth NAP B.V.	10% Owner	Dec 17 '24	Sale	25.95	114,384	2,968,756	11,009,230	Dec 18 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 16 '24	Sale	25.00	1,096	27,400	11,123,614	Dec 18 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 12 '24	Sale	25.39	166,011	4,215,827	11,150,461	Dec 16 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 13 '24	Sale	25.01	25,751	644,048	11,124,710	Dec 16 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 10 '24	Sale	25.37	308,250	7,818,808	11,470,510	Dec 12 04:15 PM
ForGrowth NAP B.V.	10% Owner	Dec 11 '24	Sale	25.46	154,038	3,921,809	11,316,472	Dec 12 04:15 PM
ForGrowth NAP B.V.	10% Owner	Nov 18 '24	Sale	25.08	33,273	834,440	11,778,760	Nov 19 04:15 PM
ForGrowth NAP B.V.	10% Owner	Nov 15 '24	Sale	25.02	8,530	213,436	11,812,033	Nov 19 04:15 PM
ForGrowth NAP B.V.	10% Owner	Nov 14 '24	Sale	25.01	9,832	245,856	11,820,563	Nov 15 04:36 PM
ForGrowth NAP B.V.	10% Owner	Nov 13 '24	Sale	25.00	1,066	26,655	11,830,395	Nov 15 04:36 PM
NAP PoolCo B.V.	Affiliate	Nov 13 '24	Proposed Sale	24.98	1,553,759	38,812,900		Nov 13 04:23 PM
Kooij Louise Frederika	Chief Accounting Officer	Oct 01 '24	Sale	15.72	45,000	707,400	0	Oct 01 05:23 PM
Kooij Louise Frederika	Officer	Oct 01 '24	Proposed Sale	17.29	45,000	778,050		Oct 01 05:12 PM
Audet Juliette Berangere	Chief Business Officer	Sep 26 '24	Buy	15.70	1,104	17,333	1,104	Sep 30 05:22 PM
Davidson Michael H.	Chief Executive Officer	Aug 20 '24	Buy	16.27	5,000	81,350	209,784	Aug 22 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NewAmsterdam Pharma Company NV

Upgrade your FINVIZ experience